Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Tirzepatide treatment was associated with reduced body weight and diabetes risk across 3 years among individuals with obesity ...

If you’re starting a weight loss journey, you might have stumbled upon tirzepatide — the drug approved by the FDA (U.S. Food ...

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...

The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...

As the New Year begins, the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) is urging the public to avoid ...

Weight-loss injection Mounjaro, or tirzepatide, will be rolled out on the NHS gradually over a 12-year period, starting this year.

Eighty percent of doctors in a Medscape survey answered no when asked, “Is enough known about obesity meds’ risk to ...

The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.

The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...

Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...

If you’re starting a weight loss journey, you might have stumbled upon tirzepatide — the drug approved by the FDA (U.S. Food and Drug Administration) under the brand names Mounjaro and Zepbound.